Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.37M |
| Gross Profit (TTM) | $3.33M |
| EBITDA | $-8.98M |
| Operating Margin | -1583.00% |
| Return on Equity | -2543.00% |
| Return on Assets | -39.30% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $-0.04 |
| Price-to-Book | 29.40 |
| Price-to-Sales (TTM) | 10.66 |
| EV/Revenue | 3.172 |
| EV/EBITDA | -2.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 499.60% |
| Shares Outstanding | $19.67M |
| Float | $13.50M |
| % Insiders | 11.72% |
| % Institutions | 13.37% |
Volatility is currently contracting
New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic priorities
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection
Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's proprietary topical Sildenafil Cream, 3.6%
View the video webcast here
New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million
Video webcast now available here
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA's 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**
President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value over the next 12–18 months Access the segment here
National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DARE and any ticker you trade — then tracks every position and per-strategy win rate.
